

Regulatory Workshop on Clinical Trials Designs in Neuromyelitis Optica (NMO) and Spectrum Disorders

# Clinical view on current Standard of Care in NMO

#### R. MARIGNIER MD, PhD

Service de Neurologie A et Centre de Coordination EDMUS sur la Sclérose en Plaques Hôpital Neurologique Pierre Wertheimer – Lyon – France Université Claude Bernard Lyon 1 Centre de Recherche en Neurosciences de Lyon





Institut national de la santé et de la recherche médicale

#### Level of Evidence for SOC in NMO: State of the Art

- No RCT=No level A evidences
- Most studies are single-arm, open-label, with no control group, in small numbers of people
  but:
- NMO= Rare disease, 0.4 in 10,000 people in the European Union (EU)

NMO= Well characterized recently (2004-2006)

#### **Treatments for relapse prevention in NMO**

#### Immunosuppressant therapies

Azathioprine (Aza) Mycophenolate Mofetil (MMF) Methotrexate Mitoxantrone

B-cell Targeting therapy Rituximab (RTX)

New therapies Eculizumab Tocilizumab

# Standard of Care for relapse prevention in NMO: Definition

#### Immunosuppressant therapies

Azathioprine (Aza) : DNA synthesis inhibitor Mycophenolate Mofetil (MMF): cytostatic effect on T, B lymphocytes Methotrexate

Mitoxantrone


## **B-cell Targeting therapy**

Rituximab (RTX): chimeric monoclonal antibody against CD 20

**New therapies** Eculizumab Tocilizumab

#### **Standard of Care : widespread use in NMO**

Reported use of Aza and/or MMF and/or RTX in > 25 patients



Austria: Aboul-Enein et al. 2013; Brazil: Bichuetti et al 2010; China: Yang et al. 2013; France: Papeix et al. 2007; Collongues et al. 2010; Germany: Pelkofer et al., 2011; Jarius et al., 2012; Trebst et al; 2014; India: Barhati et al. 2014; Iran: Etemadifar et al.2014; Italy: Ghezzi et al. 2004; Japan: Kitley et al. 2012; Korea: Kim et al; 2011, 2013; Huh et al. 2014; Mexico: Rivera et al. 2008; Norway: Asgari et al; 2014; Spain: Saiz et al. (in preparation); UK: Kitley et al. 2012, Jacob et al. 2014; USA: Jacob et al. 2008, 2009; Constanzi et al. 2011, 5 Mealy et al. 2014

### **SOC in NMO: Guidelines and Recommendations**

#### REVIEW

Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the Neuromyelitis Optica Study Group (NEMOS)

Corinna Trebst · Sven Jarius · Achim Berthele · Friedemann Paul · Sven Schippling · Brigitte Wildemann · Nadja Borisow · Ingo Kleiter · Orhan Aktas · Tania Kümpfel · Neuromyelitis Optica Study Group (NEMOS)

J Neurol (2014) 261:1–16 DOI 10.1007/s00415-013-7169-7

European Journal of Neurology 2010

doi:10.1111/j.1468-1331.2010.03066.x

EFNS GUIDELINES

# EFNS guidelines on diagnosis and management of neuromyelitis optica

J. Sellner<sup>a</sup>, M. Boggild<sup>b</sup>, M. Clanet<sup>c</sup>, R. Q. Hintzen<sup>d</sup>, Z. Illes<sup>e</sup>, X. Montalban<sup>f</sup>, R. A. Du Pasquier<sup>g</sup>, C. H. Polman<sup>h</sup>, P. S. Sorensen<sup>i</sup> and B. Hemmer<sup>a</sup>




Treatment of Neuromyelitis Optica: Review and Recommendations Kimberley et al. for the Guthy Jackson Foundation (WorldWide)

#### **Standard of Care in NMO: Standardized regimen?**


Medication	Dose	Route	Schedule	Monitoring	Treatment Change Considerations
*Azathioprine	2 - 3 mg/kg/day	Oral	1-2 daily doses	Initial: TPMT activity assay.	If MCV did not rise on initial dose,
(+ prednisone)	(+ 30 mg/day)		(prednisone taper	Periodic: Mean corpuscular	consider increase by 0.5 – 1
			after 6 – 9 months)	volume (MCV) increase of at	mg/kg/day. Or consider increasing
				least 5 points from baseline;	dose or duration of prednisone.
				monthly liver function tests	
				for first 6 months, then twice	
				yearly; maintain absolute	
				neutrophil counts > 1000	Switch to: Rituximab or
				cells/μL.	mycophenolate mofetil.
*Mycophenolate	1000 - 3000	Oral	Two daily doses	Absolute lymphocyte count	If ALC goal cannot be reached at
mofetil	mg/day		(prednisone taper	(ALC) target of 1.0 – 1.5 k/μL;	maximum dose of 3000 mg/day,
(+ prednisone)	(+ 30 mg/day)		after 6 months)	monthly liver function tests	observe closely for relapse.
				for first 6 months, then twice	
				yearly	Switch to: Rituximab
*Rituximab	1000 mg for	IV	Two doses of 1000	Monthly CD19+ B cells	Relapses during first 3 weeks of
	adults; 375		mg 14 days apart or	starting immediately post-	initial dosing are not failures.
	mg/m <sup>2</sup> for		4 weekly doses of	infusion; if CD19+ count	Relapses when CD19+ count is
	children		375 mg/m <sup>2</sup> for	exceeds 1% of total	greater than 1% are failures due to
			children; each pair	lymphocytes, re-dose with	undertreatment.
			can be given	rituximab. If suppression of	
			routinely q6 months	CD19+ count does not occur,	
			without monitoring	consider switching to	
			of CD19 counts, or	alternative. Monitor	
			by following CD19+	immunoglobulins yearly.	
			cell counts and		
			dosing as soon as it		Switch to: Azathioprine or
			exceeds 1%.		mycophenolate mofetil.

#### SOC: physiopathological rationale in NMO



Human Pathology: Lucchinetti et al. 2002, Roemer et al. 2007, Misu et al. 2007, 2013 Animal Model: Bradl et al. 2009, Bennett et al. 2009, Saadoun et al., 2010, Kinoshita et al. 2010, Ratelade 2011 In vitrro model: Hinson et al. 2007, 2008, 2012; Sabater et al. 2009; Marignier et al. 2010, Tradtrantip et al. 2012a, 2012b

#### **Standard of Care : rationale in NMO?**



Human Pathology: Lucchinetti et al. 2002, Roemer et al. 2007, Misu et al. 2007, 2013 Animal Model: Bradl et al. 2009, Bennett et al. 2009, Saadoun et al., 2010, Kinoshita et al. 2010, Ratelade 2011 In vitrro model: Hinson et al. 2007, 2008, 2012; Sabater et al. 2009; Marignier et al. 2010, Tradtrantip et al. 2012a, 2012b

#### **Standard of Care : rationale in NMO?** Lymphocyte B +T AQP4-IgG RTX **Pro-Inflammatory** Cytokines Complement ADCC Neutrophil Eosinophil CDC Degranulation Phagocytosis, Astrocyte Macrophage Axon Demyelination Transection

APP

Human Pathology: Lucchinetti et al. 2002, Roemer et al. 2007, Misu et al. 2007, 2013 Animal Model: Bradl et al. 2009, Bennett et al. 2009, Saadoun et al., 2010, Kinoshita et al. 2010, Ratelade 2011 In vitrro model: Hinson et al. 2007, 2008, 2012; Sabater el al. 2009; Marignier et al. 2010, Tradtrantip el al. 2012a, 2012b

## **SOC:** level of evidence in other indications

## Approved

#### AZA:

- an adjunct for the prevention of rejection in renal homotransplantation
- management of active rheumatoid arthritis to reduce signs and symptoms

**MMF** (in combination with steroids and cyclosporine) :

- prevention of organ rejection assessed in randomized, double-blind, multicenter trials in renal (3 trials), in cardiac (1 trial), and in hepatic (1 trial) adult transplant patients.

#### Rituximab

- Two forms of non-Hodgkin's lymphoma
- Chronic lymphocytic leukaemia (a cancer of the B-lymphocytes)
- Severe rheumatoid arthritis together with methotrexate

-Rare autoimmune condition anti-neutrophil cytoplasmic antibody (ANCA)associated vasculitis

## **SOC:** level of evidence in other indications

## **Official recommendation**

#### AZA (NICE-UK and HAS-FRANCE)

- Severe or moderately severe inflammatory intestinal diseases (Crohn's disease or ulcerative colitis),

- Systemic lupus erythematosus
- Dermatomyositis and polymyositis
- Auto-immune hepatitis
- Polyarteritis nodosa
- Refractory warm auto-immune haemolytic anaemia
- Chronic refractory idiopathic thrombocytopenic purpura

### **SOC: level of evidence in other indications**

## Myasthenia Gravis experience

Auto-antibody mediated neuro-inflammatory disorder Pathogenic auto-antibody Rare but life-threatening Long time experience of immunosuppressive agents

#### AZA

- Several retrospective and prospective case series Witte et al. 1984; Kuks et al. 1991
- 1 RCT, 46 patients, 3 years FU: better than placebo, in addition to steroids (Palace for the Myasthenia Gravis Study Group 1998)

#### MMF

- Recommended as steroid-sparing medication


#### Rituximab

- Recommended for refractory MG
- MG associated to MuSK auto-antibodies Thakre et al. 2007; Baek et al., 2007

#### **SOC:** evidence of efficacy in NMO

#### Median ARR 10 open-label retrospective studies


Number of patients > 25 Duration of follow-up > 18 months Same endpoints




#### SOC: evidence of efficacy in NMO (2)

#### Median EDSS 9 open-label retrospective studies:


Number of patients > 25 Duration of follow-up > 18 months



#### SOC: evidence of efficacy in NMO (3)





### **SOC efficacy: Change in NMO natural history**



Effect of new diagnostic criteria??? No signal in AQP4+ group Effect on treatment: Shift from INF Beta/Cyclophosphamide to AZA/MMF/RTX

#### **SOC efficacy: harmful effect of MS-DMT**






Jacob et al. 2012 (UK)

#### Kleiter et al. 2012 (Germany)

Natalizumab



Fingolimod


### SOC efficacy: lower impact of relapse disability

#### Medication Improves Long-Term Outcome in NMO

#### Residual disability from relapses

Optic Neuritis attacks	off treatment	on treatment	
n Change in VA*, mean (SD)	34 -0.67 (0.36)	17 -0.31 (0.40)	p<0.05
% no residual change	17.6	52.9	

TM attacks	off treatment	on treatment	
n	24	12	
Change in EDMUS, mean (SD)	3 (3.17)	0.21 (3.12)	p<0.05
% no residual change	33.3	50.0	



Tackley et al. 2014, ECTRIMS

Abboud et al. 2014, ECTRIMS

# SOC in NMO: differences in approach or effect by major subgroups?

## **Pediatric population**

- AZA/MMF/RTX has been used in pediatric cohorts (Mc Keon et al. 2008, Lotze et al. 2008, Collongues et al., 2010)

- Recommendation-Guidelines: same than in adults (Tenenbaum 2013)

Overview of immunosuppressive drug use in the treatment of paediatric NMO.

Drug	Date	Lead Author	Location	Population size	Impact on attacks
Azathioprine	2007	Djemal [81]	Tunisia	1	1 attack-free
•	2008	McKeon [49]	United States	10	5 attack-free; 2 reduced attack rate
18/24	2008	Lotze [71]	United States	1	1 needed switch to other drug
	2008	Loma [82]	United States	1	1 attack-free
	2010	Collongues [73]	France	4	1/4 needed switch to other drug
	2011	Peña [83]	Venezuela	5	Not reported
	2011	Costanzi [66]	United States	7	6/7 reduced attack rate1/7 discontinued due to SE
Mycophenolate mofetil	2006	Falcini [79]	Italy	1	1 attack-free
C / 0	2008	McKeon [49]	United States	3	2/3 attack-free
6/8	2008	Lotze [71]	United States	6	Not reported
	2010	Collongues [73]	France	4	1/4 needed switch to other drug
Rituximab	2008	McKeon [49]	United States	8	7/8 attack-free
9/10	2008	Lotze [71]	United States	5	Not reported
9/10	2010	Collongues [73]	France	1	Not reported
	2011	Mahmood [74]	United States	2	2 attack-free
Methotrexate	2008	McKeon [49]	United States	1	1 attack-free
Cyclophosphamide	2008	McKeon [49]	United States	2	2 needed switch to other drug
• • •	2008	Banwell [48]	Canada and Argentina	2	2 needed switch to other drug
2/9	2010	Collongues [73]	France	5	3/5 needed switch to other drug
Mitoxantrone	2010	Collongues [73]	France	1	1 needed switch to other drug

# SOC in NMO: differences in approach or effect by major subgroups?

## **NMO spectrum disorder**

Most of the studies included

- genuine NMO (Wingerchuck 1999, Wingerchuck 2006) and NMO Spectrum Disorder (Wingerchuck 2007) AQP4+ LETM, AQP4+ ON
- NMO and NMOSD AQP4-IgG share the same physiopathology (Yanagawa et al. 2009)
- Recommendation Guidelines (Kimbrough et al. 2012):

*"For NMO or NMOSD patients with established relapsing disease, long term immunosuppression .... are recommended"* 

## AQP4+/AQP4-

- AQP4-IgG negative NMO express some specific features including a possible better outcome (Jarius et al. 2013, Marignier et al. 2013, Marignier et al. 2014)

- AQP4-IgG negative NMO are associated to MOG-IgG (Mader et al. 2011, Reindl 2013)
- MOG-IgG NMO are associated to better outcome (Sato et a. 2014, Kitley et al. 2014)
- No recommendation yet for MOG-IgG but immunoactive treatment might be useful

### **SOC in NMO: summary**

- 1) Mechanism of action
- 2) Long-time experience of efficacy and safety in inflammatory disorders and Ab-mediated disorders
- 3) No harmful signal in NMO (≠MS DMT)
- 4) Accumulative direct and indirect evidences for efficacy and reasonable safety in NMO
- 5) Widespread use and access (Asia, Europe, Latin America, USA)
- 6) Broad range of efficacy: differential diagnosis of NMO (useful in seroneg cases)
- 7) Practise supported by national and international Guidelines and recommendations

The strength of evidence is related to what the evidence is *for*, and **good evidence for clinical decisions should answer clinically relevant questions**.

What the clinician, patient, or policy maker wants to know (amongst other things) is:

'Which treatment, from among all the available alternatives, has the most favourable benefit/harm balance?'

Oxford Centre for Evidence-Based Medicine (OCEBM)

#### **Clinically relevant unmet needs in NMO:**

Higher level of evidence for SOC A new treatment with a more favourable benefit/harm balance than SOC